Receptor-blocking antibody
Antibody signal-receptor blockade
- Binds the RECEPTOR and caps it, so the cytokine can no longer signal through it
- Dupilumab at IL-4Rα blocks IL-4 and IL-13 at once without binding either cytokine
- Erenumab blocks the CGRP receptor; galcanezumab and fremanezumab bind the CGRP ligand instead
- Tocilizumab and sarilumab at IL-6R normalize CYP activity as inflammation falls — check the interaction arrow
- Binds the RECEPTOR and caps it, so the cytokine can no longer signal through it
- Dupilumab at IL-4Rα blocks IL-4 and IL-13 at once without binding either cytokine
- Erenumab blocks the CGRP receptor; galcanezumab and fremanezumab bind the CGRP ligand instead
- Tocilizumab and sarilumab at IL-6R normalize CYP activity as inflammation falls — check the interaction arrow
Drugs with this mechanism (6)
- Anifrolumab — Type I interferon-receptor antibody for systemic lupus; especially useful for cutaneous disease.
- Dupilumab — IL-4 receptor alpha antibody that blocks both IL-4 and IL-13 signaling.
- Erenumab — CGRP receptor antibody for monthly migraine prevention.
- Sarilumab — IL-6 receptor antibody for rheumatoid arthritis.
- Teprotumumab — IGF-1R antibody for thyroid eye disease; eight IV infusions over 21 weeks.
- Tocilizumab — IL-6 receptor antibody for rheumatoid arthritis and cytokine release syndrome.
All mechanisms · Open Antibody signal-receptor blockade in the interactive console ↗